SNT
SYNTARA LIMITEDSyntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate is amsulostat, which has completed Phase 2a clinical trial for the treatment of bone marrow cancer myelofibrosis, as well as in Phase 1c/2 clinical trial for patients with myelodysplastic syndrome and in Phase 1/2 clinical trial to treat pancreatic cancer. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for the treatment of keloid scars; and SNT-4728 to treat sleep behaviour disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation. In addition, it develops other drug candidates to treat fibrotic and inflammatory diseases, including kidney fibrosis, MASH, pulmonary fibrosis, and cardiac fibrosis. The company has a collaboration agreement with the University of Western Australia to studying SNT-6302 in keloid scars. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
SNT
SNT
SYNTARA LIMITED
Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate is amsulostat, which has completed Phase 2a clinical trial for the treatment of bone marrow cancer myelofibrosis, as well as in Phase 1c/2 clinical trial for patients with myelodysplastic syndrome and in Phase 1/2 clinical trial to treat pancreatic cancer.
Fundamentals
Historical Data44 days
| Date | Short % | Gross Short |
|---|---|---|
| 5 Aug | — | — |
| 4 Aug | — | — |
| 3 Aug | — | — |
| 31 July | — | — |
| 30 July | — | — |
| 29 July | — | — |
| 28 July | — | — |
| 27 July | — | — |
| 24 July | — | — |
| 23 July | — | — |
| 22 July | — | — |
| 21 July | — | — |
Syntara Limited (SNT) Short Interest Summary
Syntara Limited (SNT) currently has 0.24% of its shares sold short (4.8 million shares, worth approximately $139K), based on ASIC short position data reported on 7 July 2026 (T+4 reporting lag). That makes SNT the #392 most shorted stock on the ASX most shorted list. SNT is part of the Health Care sector on the ASX.
Recent SNT Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 7 July 2026 | 0.24% | 4.8M | $0.02 |
| 3 June 2026 | 0.00% | 0.0M | $0.03 |
| 2 June 2026 | 0.00% | 0.0M | $0.03 |
SNT Short Selling — Frequently Asked Questions
What is Syntara Limited (SNT)'s current short interest?
Syntara Limited (SNT) currently has a short interest of 0.24% of total shares outstanding. This means 0.24% of SNT's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is SNT heavily shorted on the ASX?
SNT has a relatively low short interest of 0.24%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for SNT investors?
Short interest in SNT shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.24%, SNT's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this SNT short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for SNT.